The Mount Sinai CCOP (MSCCOP) is comprised of one component and four affiliate members;It will celebrate its 26th year as an NCI-supported program in 2013. It has been a consistent leader in minority accrual nationwide with particular emphasis on the Hispanic population. The MSCCOP seeks to continue to meet the community's need for innovative and relevant studies of promising therapeutic modalities and cancer control research. The ongoing mission of the MSCCOP is to assure that every person in the region served is provided an opportunity for participation in national cancer prevention and treatment clinical trials. Additionally we offer ongoing education about cancer and the NCI clinical trials program to both health care professionals and the community. This grant application encompasses and articulates an ongoing vision for the MSCCOP with goals that include: (a) increased patient access and accrual to cancer treatment, prevention and control protocols;(b) increased accrual of minorities, women, and underserved populations;(c) establishment of a stronger and more cohesive affiliate network;(d) strengthened relationships with and contributions to affiliated research bases;(e) maintenance of high-quality data management. Key strategies to increase patient access and accrual to research protocols include expanding participation in symptom management studies, strengthening partnerships with community organizations serving the Hispanic community, increasing participation with newly-consolidated NCI cooperative groups, and improving systems and services that will benefit affiliate institutions.
The Community Clinical Oncology Program (CCOP) links community cancer specialists, primary care physicians, and other health care professionals to the NCI-supported Cooperative Groups and Cancer Centers to conduct NCI-approved cancer treatment, prevention, and control clinical trials. The MSCCOP is the only CCOP in south Florida serving adults and is a major resource for the Hispanic community.
|Heist, Rebecca S; Wang, Xiaofei; Hodgson, Lydia et al. (2014) CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 9:214-21|
|Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89|
|Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38|
|Aggarwal, Rahul; Halabi, Susan; Kelly, William Kevin et al. (2013) The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer 119:3636-43|
|Romanus, Dorothy; Kindler, Hedy L; Archer, Laura et al. (2012) Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage 43:205-17|
|Lichtman, S M; Hurria, A; Cirrincione, C T et al. (2012) Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Ann Oncol 23:632-8|
|Baer, M R; George, S L; Sanford, B L et al. (2011) Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. Leukemia 25:800-7|
|Mamon, Harvey J; Niedzwiecki, Donna; Hollis, Donna et al. (2011) A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003. Cancer 117:2620-8|
|Graziano, Stephen L; Gu, Lin; Wang, Xiaofei et al. (2010) Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. J Thorac Oncol 5:810-7|
|Lyss, Alan P; Lilenbaum, Rogerio C (2009) Accrual to National Cancer Institute-sponsored non-small-cell lung cancer trials: insights and contributions from the CCOP program. Clin Lung Cancer 10:410-3|
Showing the most recent 10 out of 30 publications